Core Insights - Progyny, Inc. reported a quarterly revenue of 52.2 million in quarterly operating cash flow and provided financial guidance for 2025, projecting revenue growth of 1% to 5% [1][28] - The CEO highlighted improved member engagement trends as the company enters its tenth year in the market, emphasizing the unique approach to value-based care [2][3] Financial Highlights - Fourth Quarter 2024 Results: - Revenue: 269.9 million in Q4 2023 [4][8] - Gross Profit: 56.9 million in Q4 2023 [9] - Net Income: 0.12 per diluted share, down from 0.13 per diluted share in Q4 2023 [10][11] - Adjusted EBITDA: 43.2 million in Q4 2023 [11] - Full Year 2024 Results: - Revenue: 1,088.6 million in 2023 [12] - Gross Profit: 238.8 million in 2023 [13] - Net Income: 0.57 per diluted share, down from 0.62 per diluted share in 2023 [14] - Adjusted EBITDA: 187.1 million in 2023 [15] Cash Flow and Financial Position - Net cash provided by operating activities for 2024 was 188.8 million in 2023 [17] - As of December 31, 2024, the company had total working capital of approximately 52.5 million in Q4 2024, totaling 12,382,193 shares repurchased in 2024 [22] Client and Market Metrics - The company had 473 clients as of December 31, 2024, compared to 392 clients a year earlier [23] - Fertility benefit services revenue was 171.3 million in Q4 2023 [19] - Pharmacy benefit services revenue was 98.6 million in Q4 2023 [19] Financial Outlook - For the full year 2025, revenue is projected to be between 1.225 billion, with net income expected to be between 53.9 million [28] - For Q1 2025, revenue is projected to be between 318.0 million, reflecting growth of 8% to 14% [28]
Progyny, Inc. Announces Fourth Quarter 2024 Results